Pay in 4 interest-free payments of $5.19 Learn more
Ships within 48 hours Β· Estimated delivery Aug 12 - Aug 17
Taylor SI, Blau JE, Rother KI, Beitelshees AL (2019) SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: balancing benefits and risks
Funding This work was supported by National Natural Science Foundation of China (82101674 to C.N.)
Long-term benefits may include: Continued fat loss Improved metabolic health Better long-term weight maintenance Increased confidence and quality of life What Do Clinical Studies Show
Additionally, the aetiology of type 2 diabetes and the ultimate causes are not completely understood
H., Abdallah, M
In phase 2 clinical trials published in the New England Journal of Medicine (2023), it demonstrated substantial weight loss outcomes, largely attributed to its ability to influence hunger signals particularly in the hypothalamus, which governs satiety and energy balance
